Anthropic CEO Dario Amodei Pledges at Nasdaq Opening Bell to Pace AI Deployment and Resist Commercial or...
Speaking at the Nasdaq MarketSite opening bell ceremony on Thursday, November 19, to mark Anthropic's ($ANT) record $81.34 billion initial public offering, co-founder and CEO Dario Amodei outlined the company's scientific mission while vowing that public market scrutiny will not compromise its AI safety standards.
Key themes and commitments from Amodei's IPO-day address include:
* Compressing a century of medical progress into a decade: Recalling how he and co-founder Daniela Amodei lost their father to a disease that became curable just years later, Amodei stated that "sufficiently powerful AI, working in concert with humans, could compress a century of scientific and medical progress into a decade"—highlighting ongoing applications in protein folding, drug design, cancer genetics, and clinical trial administration while noting that empirical validation remains essential.
* Unwavering refusal to bow to commercial or political pressure: Acknowledging risks ranging from nation-state misuse to loss of human control over advanced systems, Amodei declared unequivocally: "We will pace the training and deployment of AI systems, taking as long as is necessary to have confidence that they are safe and will remain under human control. We will not bend to either business nor political pressure."
* Driving an industry-wide "race to the top": Structured as a public benefit corporation, Anthropic aims to use its strengthened post-IPO balance sheet to prove that rigorous safety governance and commercial scale can coexist—challenging rival frontier labs to compete on safety standards rather than reckless deployment speed.